TY - JOUR AU - Nasrazadani, A. AU - Thomas, R. A. AU - Oesterreich, S. AU - Lee, A. V. PY - 2018 DA - 2018// TI - Precision medicine in hormone receptor-positive breast Cancer JO - Front Oncol VL - 8 UR - https://doi.org/10.3389/fonc.2018.00144 DO - 10.3389/fonc.2018.00144 ID - Nasrazadani2018 ER - TY - JOUR AU - Slamon, D. AU - Eiermann, W. AU - Robert, N. PY - 2011 DA - 2011// TI - Breast Cancer international research G. adjuvant trastuzumab in HER2-positive breast cancer JO - N Engl J Med VL - 365 UR - https://doi.org/10.1056/NEJMoa0910383 DO - 10.1056/NEJMoa0910383 ID - Slamon2011 ER - TY - JOUR AU - Sorlie, T. AU - Tibshirani, R. AU - Parker, J. PY - 2003 DA - 2003// TI - Repeated observation of breast tumor subtypes in independent gene expression data sets JO - Proc Natl Acad Sci U S A VL - 100 UR - https://doi.org/10.1073/pnas.0932692100 DO - 10.1073/pnas.0932692100 ID - Sorlie2003 ER - TY - JOUR AU - Marchio, C. AU - Natrajan, R. AU - Shiu, K. K. PY - 2008 DA - 2008// TI - The genomic profile of HER2-amplified breast cancers: the influence of ER status JO - J Pathol VL - 216 UR - https://doi.org/10.1002/path.2423 DO - 10.1002/path.2423 ID - Marchio2008 ER - TY - JOUR AU - Ng, C. K. AU - Schultheis, A. M. AU - Bidard, F. C. PY - 2015 DA - 2015// TI - Breast cancer genomics from microarrays to massively parallel sequencing: Paradigms and new insights JO - J Natl Cancer Inst VL - 107 UR - https://doi.org/10.1093/jnci/djv015 DO - 10.1093/jnci/djv015 ID - Ng2015 ER - TY - JOUR AU - Wirapati, P. AU - Sotiriou, C. AU - Kunkel, S. PY - 2008 DA - 2008// TI - Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures JO - Breast Cancer Res VL - 10 UR - https://doi.org/10.1186/bcr2124 DO - 10.1186/bcr2124 ID - Wirapati2008 ER - TY - JOUR AU - Gianni, L. AU - Eiermann, W. AU - Semiglazov, V. PY - 2014 DA - 2014// TI - Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort JO - Lancet Oncol VL - 15 UR - https://doi.org/10.1016/S1470-2045(14)70080-4 DO - 10.1016/S1470-2045(14)70080-4 ID - Gianni2014 ER - TY - JOUR AU - Gianni, L. AU - Eiermann, W. AU - Semiglazov, V. PY - 2010 DA - 2010// TI - Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort JO - Lancet VL - 375 UR - https://doi.org/10.1016/S0140-6736(09)61964-4 DO - 10.1016/S0140-6736(09)61964-4 ID - Gianni2010 ER - TY - JOUR AU - Modica, M. AU - Tagliabue, E. AU - Triulzi, T. PY - 2017 DA - 2017// TI - Predicting the efficacy of HER2-targeted therapies: a look at the host JO - Dis Markers VL - 2017 UR - https://doi.org/10.1155/2017/7849108 DO - 10.1155/2017/7849108 ID - Modica2017 ER - TY - JOUR AU - Brodsky, A. S. AU - Xiong, J. AU - Yang, D. PY - 2016 DA - 2016// TI - Identification of stromal ColXalpha1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer JO - BMC Cancer VL - 16 UR - https://doi.org/10.1186/s12885-016-2302-5 DO - 10.1186/s12885-016-2302-5 ID - Brodsky2016 ER - TY - JOUR AU - Bonnans, C. AU - Chou, J. AU - Werb, Z. PY - 2014 DA - 2014// TI - Remodelling the extracellular matrix in development and disease JO - Nat Rev Mol Cell Biol VL - 15 UR - https://doi.org/10.1038/nrm3904 DO - 10.1038/nrm3904 ID - Bonnans2014 ER - TY - JOUR AU - Kota, J. AU - Hancock, J. AU - Kwon, J. AU - Korc, M. PY - 2017 DA - 2017// TI - Pancreatic cancer: stroma and its current and emerging targeted therapies JO - Cancer Lett VL - 391 UR - https://doi.org/10.1016/j.canlet.2016.12.035 DO - 10.1016/j.canlet.2016.12.035 ID - Kota2017 ER - TY - JOUR AU - Gascard, P. AU - Tlsty, T. D. PY - 2016 DA - 2016// TI - Carcinoma-associated fibroblasts: orchestrating the composition of malignancy JO - Genes Dev VL - 30 UR - https://doi.org/10.1101/gad.279737.116 DO - 10.1101/gad.279737.116 ID - Gascard2016 ER - TY - JOUR AU - Pickup, M. W. AU - Laklai, H. PY - 2013 DA - 2013// TI - Stromally derived lysyl oxidase promotes metastasis of transforming growth factor-beta-deficient mouse mammary carcinomas JO - Cancer Res VL - 73 UR - https://doi.org/10.1158/0008-5472.CAN-13-0012 DO - 10.1158/0008-5472.CAN-13-0012 ID - Pickup2013 ER - TY - JOUR AU - Denkert, C. AU - Loibl, S. AU - Noske, A. PY - 2010 DA - 2010// TI - Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2009.23.7370 DO - 10.1200/JCO.2009.23.7370 ID - Denkert2010 ER - TY - JOUR AU - Hammond, M. E. AU - Hayes, D. F. AU - Dowsett, M. PY - 2010 DA - 2010// TI - American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer JO - Archives of pathology and laboratory medicine VL - 134 ID - Hammond2010 ER - TY - JOUR AU - Wolff, A. C. AU - Hammond, M. E. H. AU - Allison, K. H. PY - 2018 DA - 2018// TI - Human epidermal growth factor receptor 2 testing in breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2018.77.8738 DO - 10.1200/JCO.2018.77.8738 ID - Wolff2018 ER - TY - JOUR PY - 2015 DA - 2015// TI - The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs working group JO - Ann Oncol VL - 26 UR - https://doi.org/10.1093/annonc/mdu450 DO - 10.1093/annonc/mdu450 ID - ref18 ER - TY - BOOK PY - 2015 DA - 2015// TI - Analysis-ready standardized TCGA data from broad GDAC firehose stddata__2015_06_01 run PB - Broad Institute of MIT and Harvard CY - Dataset ID - ref19 ER - TY - JOUR AU - Carey, L. A. AU - Perou, C. M. AU - Livasy, C. A. PY - 2006 DA - 2006// TI - Race, breast cancer subtypes, and survival in the Carolina breast Cancer study JO - JAMA VL - 295 UR - https://doi.org/10.1001/jama.295.21.2492 DO - 10.1001/jama.295.21.2492 ID - Carey2006 ER - TY - JOUR AU - Onitilo, A. A. AU - Engel, J. M. AU - Greenlee, R. T. AU - Mukesh, B. N. PY - 2009 DA - 2009// TI - Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival JO - Clin Med Res VL - 7 UR - https://doi.org/10.3121/cmr.2008.825 DO - 10.3121/cmr.2008.825 ID - Onitilo2009 ER - TY - JOUR AU - Goldhirsch, A. AU - Winer, E. P. AU - Coates, A. S. PY - 2013 DA - 2013// TI - Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast Cancer 2013 JO - Ann Oncol VL - 24 UR - https://doi.org/10.1093/annonc/mdt303 DO - 10.1093/annonc/mdt303 ID - Goldhirsch2013 ER - TY - JOUR AU - McGuire, A. AU - Kalinina, O. AU - Holian, E. AU - Curran, C. AU - Malone, C. A. AU - McLaughlin, R. PY - 2017 DA - 2017// TI - Differential impact of hormone receptor status on survival and recurrence for HER2 receptor-positive breast cancers treated with Trastuzumab JO - Breast Cancer Res Treat VL - 164 UR - https://doi.org/10.1007/s10549-017-4225-5 DO - 10.1007/s10549-017-4225-5 ID - McGuire2017 ER - TY - JOUR AU - Kennecke, H. AU - Yerushalmi, R. AU - Woods, R. PY - 2010 DA - 2010// TI - Metastatic behavior of breast cancer subtypes JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2009.25.9820 DO - 10.1200/JCO.2009.25.9820 ID - Kennecke2010 ER - TY - JOUR AU - Vaz-Luis, I. AU - Ottesen, R. A. AU - Hughes, M. E. PY - 2012 DA - 2012// TI - Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study JO - Breast Cancer Res VL - 14 UR - https://doi.org/10.1186/bcr3324 DO - 10.1186/bcr3324 ID - Vaz-Luis2012 ER - TY - JOUR AU - Ribelles, N. AU - Perez-Villa, L. AU - Jerez, J. M. PY - 2013 DA - 2013// TI - Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index JO - Breast Cancer Res VL - 15 UR - https://doi.org/10.1186/bcr3559 DO - 10.1186/bcr3559 ID - Ribelles2013 ER - TY - JOUR AU - Lowery, A. J. AU - Kell, M. R. AU - Glynn, R. W. PY - 2011 DA - 2011// TI - Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype JO - Breast Cancer Res Treat VL - 133 UR - https://doi.org/10.1007/s10549-011-1891-6 DO - 10.1007/s10549-011-1891-6 ID - Lowery2011 ER - TY - JOUR AU - Osborne, C. K. AU - Bardou, V. AU - Hopp, T. A. PY - 2003 DA - 2003// TI - Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer JO - J Natl Cancer Inst VL - 95 UR - https://doi.org/10.1093/jnci/95.5.353 DO - 10.1093/jnci/95.5.353 ID - Osborne2003 ER - TY - JOUR AU - Laurentiis, M. AU - Arpino, G. AU - Massarelli, E. PY - 2005 DA - 2005// TI - A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer JO - Clin Cancer Res VL - 11 UR - https://doi.org/10.1158/1078-0432.CCR-04-2569 DO - 10.1158/1078-0432.CCR-04-2569 ID - Laurentiis2005 ER - TY - JOUR AU - Shou, J. AU - Massarweh, S. AU - Osborne, C. K. PY - 2004 DA - 2004// TI - Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2- positive breast cancer JO - J Natl Cancer Inst VL - 96 UR - https://doi.org/10.1093/jnci/djh166 DO - 10.1093/jnci/djh166 ID - Shou2004 ER - TY - JOUR AU - Ioachim, E. AU - Charchanti, A. AU - Briasoulis, E. PY - 2002 DA - 2002// TI - Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression JO - Eur J Cancer VL - 38 UR - https://doi.org/10.1016/S0959-8049(02)00210-1 DO - 10.1016/S0959-8049(02)00210-1 ID - Ioachim2002 ER - TY - JOUR AU - Conklin, M. W. AU - Keely, P. J. PY - 2012 DA - 2012// TI - Why the stroma matters in breast cancer: insights into breast cancer patient outcomes through the examination of stromal biomarkers JO - Cell Adhes Migr VL - 6 UR - https://doi.org/10.4161/cam.20567 DO - 10.4161/cam.20567 ID - Conklin2012 ER - TY - JOUR AU - Aoudjit, F. AU - Vuori, K. PY - 2001 DA - 2001// TI - Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells JO - Oncogene VL - 20 UR - https://doi.org/10.1038/sj.onc.1204554 DO - 10.1038/sj.onc.1204554 ID - Aoudjit2001 ER - TY - JOUR AU - Jobling, R. AU - D'Souza, R. AU - Baker, N. PY - 2014 DA - 2014// TI - The collagenopathies: review of clinical phenotypes and molecular correlations JO - Curr Rheumatol Rep VL - 16 UR - https://doi.org/10.1007/s11926-013-0394-3 DO - 10.1007/s11926-013-0394-3 ID - Jobling2014 ER - TY - JOUR AU - Finak, G. AU - Bertos, N. AU - Pepin, F. PY - 2008 DA - 2008// TI - Stromal gene expression predicts clinical outcome in breast cancer JO - Nat Med VL - 14 UR - https://doi.org/10.1038/nm1764 DO - 10.1038/nm1764 ID - Finak2008 ER - TY - STD TI - Ma XJ, Dahiya S, Richardson E, Erlander M, Sgroi DC. (2009) Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res 11(1):R7.Conklin MW, Eickhoff JC, Riching KM, et al (2011). ID - ref36 ER - TY - STD TI - Aligned collagen is a prognostic signature for survival in human breast carcinoma. Am J Pathol 178(3):1221–1232. ID - ref37 ER - TY - STD TI - Marr MTn, Marr MTn, D & apos, Alessio JA (2007) IRES-mediated functional coupling of transcription and translation amplifies insulin receptor feedback. Genes Dev 21(2):175–183. ID - ref38 ER - TY - JOUR AU - Acerbi, I. AU - Cassereau, L. AU - Dean, I. PY - 2015 DA - 2015// TI - Human breast cancer invasion and aggression correlates with ECM stiffening and immune cell infiltration JO - Integr Biol (Camb) VL - 7 UR - https://doi.org/10.1039/c5ib00040h DO - 10.1039/c5ib00040h ID - Acerbi2015 ER - TY - JOUR AU - Chapman, K. B. AU - Prendes, M. J. AU - Sternberg, H. PY - 2012 DA - 2012// TI - COL10A1 expression is elevated in diverse solid tumor types and is associated with tumor vasculature JO - Future Oncol VL - 8 UR - https://doi.org/10.2217/fon.12.79 DO - 10.2217/fon.12.79 ID - Chapman2012 ER - TY - JOUR AU - Huang, H. AU - Li, T. AU - Ye, G. AU - Zhao, L. AU - Zhang, Z. AU - Mo, D. PY - 2018 DA - 2018// TI - High expression of COL10A1 is associated with poor prognosis in colorectal cancer JO - OncoTargets and Therapy VL - 11 UR - https://doi.org/10.2147/OTT.S160196 DO - 10.2147/OTT.S160196 ID - Huang2018 ER - TY - STD TI - Wang Y, Lu S, Xiong J, Singh K, Hui Y, Zhao C, et al. ColXα1 is a stromal component that Colocalizes with elastin in the breast tumor extracellular matrix. J Pathol Clin Res. 2018;(Sep 12). ID - ref42 ER - TY - JOUR AU - Raghav, K. P. S. AU - Hernandez-Aya, L. F. AU - Lei, X. PY - 2012 DA - 2012// TI - Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers JO - Cancer VL - 118 UR - https://doi.org/10.1002/cncr.26431 DO - 10.1002/cncr.26431 ID - Raghav2012 ER - TY - STD TI - Baehner FL, Watson D, Shak S, et al (2006) Quantitative RT-PCR analysis of ER and PR by Oncotype DX indicates distinct and different associations with prognosis and prediction of tamoxifen benefit [abstract 45]. In 29th Annual San Antonio Breast Cancer Symposium 2006. ID - ref44 ER -